OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study
Philip Ambery, Victoria E R Parker, Michael Stümvoll, et al.
The Lancet (2018) Vol. 391, Iss. 10140, pp. 2607-2618
Closed Access | Times Cited: 268
Philip Ambery, Victoria E R Parker, Michael Stümvoll, et al.
The Lancet (2018) Vol. 391, Iss. 10140, pp. 2607-2618
Closed Access | Times Cited: 268
Showing 1-25 of 268 citing articles:
Glucagon-like peptide 1 (GLP-1)
Timo D. Müller, Brian Finan, Stephen R. Bloom, et al.
Molecular Metabolism (2019) Vol. 30, pp. 72-130
Open Access | Times Cited: 1306
Timo D. Müller, Brian Finan, Stephen R. Bloom, et al.
Molecular Metabolism (2019) Vol. 30, pp. 72-130
Open Access | Times Cited: 1306
Metabolically Healthy Obesity
Matthias Blüher
Endocrine Reviews (2020) Vol. 41, Iss. 3
Open Access | Times Cited: 725
Matthias Blüher
Endocrine Reviews (2020) Vol. 41, Iss. 3
Open Access | Times Cited: 725
LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept
Tamer Coşkun, Kyle W. Sloop, Corina Loghin, et al.
Molecular Metabolism (2018) Vol. 18, pp. 3-14
Open Access | Times Cited: 575
Tamer Coşkun, Kyle W. Sloop, Corina Loghin, et al.
Molecular Metabolism (2018) Vol. 18, pp. 3-14
Open Access | Times Cited: 575
Long-Term Efficacy and Safety of Anti-Obesity Treatment: Where Do We Stand?
Young Jin Tak, Sang Yeoup Lee
Current Obesity Reports (2021) Vol. 10, Iss. 1, pp. 14-30
Open Access | Times Cited: 261
Young Jin Tak, Sang Yeoup Lee
Current Obesity Reports (2021) Vol. 10, Iss. 1, pp. 14-30
Open Access | Times Cited: 261
Emerging Role of SGLT-2 Inhibitors for the Treatment of Obesity
Maria J. Pereira, Jan W. Eriksson
Drugs (2019) Vol. 79, Iss. 3, pp. 219-230
Open Access | Times Cited: 257
Maria J. Pereira, Jan W. Eriksson
Drugs (2019) Vol. 79, Iss. 3, pp. 219-230
Open Access | Times Cited: 257
Signaling pathways in obesity: mechanisms and therapeutic interventions
Xue Wen, Bohan Zhang, Beiyi Wu, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 242
Xue Wen, Bohan Zhang, Beiyi Wu, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 242
Effects of Cotadutide on Metabolic and Hepatic Parameters in Adults With Overweight or Obesity and Type 2 Diabetes: A 54-Week Randomized Phase 2b Study
Rajaa Nahra, Tao Wang, Kishore M. Gadde, et al.
Diabetes Care (2021) Vol. 44, Iss. 6, pp. 1433-1442
Open Access | Times Cited: 231
Rajaa Nahra, Tao Wang, Kishore M. Gadde, et al.
Diabetes Care (2021) Vol. 44, Iss. 6, pp. 1433-1442
Open Access | Times Cited: 231
Pharmacotherapy of obesity: Available medications and drugs under investigation
Eleni Pilitsi, Olivia M. Farr, Stergios A. Pοlyzos, et al.
Metabolism (2018) Vol. 92, pp. 170-192
Open Access | Times Cited: 229
Eleni Pilitsi, Olivia M. Farr, Stergios A. Pοlyzos, et al.
Metabolism (2018) Vol. 92, pp. 170-192
Open Access | Times Cited: 229
Glucagon-like peptide-1 receptor co-agonists for treating metabolic disease
Laurie L. Baggio, Daniel J. Drucker
Molecular Metabolism (2020) Vol. 46, pp. 101090-101090
Open Access | Times Cited: 220
Laurie L. Baggio, Daniel J. Drucker
Molecular Metabolism (2020) Vol. 46, pp. 101090-101090
Open Access | Times Cited: 220
Treatment of type 2 diabetes: challenges, hopes, and anticipated successes
Michael A. Nauck, Jakob Wefers, Juris J. Meier
The Lancet Diabetes & Endocrinology (2021) Vol. 9, Iss. 8, pp. 525-544
Closed Access | Times Cited: 203
Michael A. Nauck, Jakob Wefers, Juris J. Meier
The Lancet Diabetes & Endocrinology (2021) Vol. 9, Iss. 8, pp. 525-544
Closed Access | Times Cited: 203
Resolution of NASH and hepatic fibrosis by the GLP-1R and GCGR dual-agonist cotadutide via modulating mitochondrial function and lipogenesis
Michelle L. Boland, Rhianna C. Laker, Karly M. Mather, et al.
Nature Metabolism (2020) Vol. 2, Iss. 5, pp. 413-431
Open Access | Times Cited: 192
Michelle L. Boland, Rhianna C. Laker, Karly M. Mather, et al.
Nature Metabolism (2020) Vol. 2, Iss. 5, pp. 413-431
Open Access | Times Cited: 192
Pharmacological treatment of hyperglycemia in type 2 diabetes
Simeon I. Taylor, Zhinous Shahidzadeh Yazdi, Amber L. Beitelshees
Journal of Clinical Investigation (2021) Vol. 131, Iss. 2
Open Access | Times Cited: 181
Simeon I. Taylor, Zhinous Shahidzadeh Yazdi, Amber L. Beitelshees
Journal of Clinical Investigation (2021) Vol. 131, Iss. 2
Open Access | Times Cited: 181
Weight loss variability with SGLT2 inhibitors and GLP‐1 receptor agonists in type 2 diabetes mellitus and obesity: Mechanistic possibilities
Emily Brown, John Wilding, Thomas M. Barber, et al.
Obesity Reviews (2019) Vol. 20, Iss. 6, pp. 816-828
Open Access | Times Cited: 174
Emily Brown, John Wilding, Thomas M. Barber, et al.
Obesity Reviews (2019) Vol. 20, Iss. 6, pp. 816-828
Open Access | Times Cited: 174
Drug Therapy in Obesity: A Review of Current and Emerging Treatments
David M. Williams, Asif Nawaz, Marc Evans
Diabetes Therapy (2020) Vol. 11, Iss. 6, pp. 1199-1216
Open Access | Times Cited: 166
David M. Williams, Asif Nawaz, Marc Evans
Diabetes Therapy (2020) Vol. 11, Iss. 6, pp. 1199-1216
Open Access | Times Cited: 166
Insights into the molecular targets and emerging pharmacotherapeutic interventions for nonalcoholic fatty liver disease
Chander K. Negi, Pavel Babica, Lola Bajard, et al.
Metabolism (2021) Vol. 126, pp. 154925-154925
Open Access | Times Cited: 163
Chander K. Negi, Pavel Babica, Lola Bajard, et al.
Metabolism (2021) Vol. 126, pp. 154925-154925
Open Access | Times Cited: 163
Insulin resistance and insulin sensitizing agents
Lucia Mastrototaro, Michael Roden
Metabolism (2021) Vol. 125, pp. 154892-154892
Open Access | Times Cited: 162
Lucia Mastrototaro, Michael Roden
Metabolism (2021) Vol. 125, pp. 154892-154892
Open Access | Times Cited: 162
LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept
Tamer Coşkun, Shweta Urva, William C. Roell, et al.
Cell Metabolism (2022) Vol. 34, Iss. 9, pp. 1234-1247.e9
Open Access | Times Cited: 158
Tamer Coşkun, Shweta Urva, William C. Roell, et al.
Cell Metabolism (2022) Vol. 34, Iss. 9, pp. 1234-1247.e9
Open Access | Times Cited: 158
Glucagon Receptor Signaling and Glucagon Resistance
Lina Janah, Sasha A. S. Kjeldsen, Katrine D. Galsgaard, et al.
International Journal of Molecular Sciences (2019) Vol. 20, Iss. 13, pp. 3314-3314
Open Access | Times Cited: 157
Lina Janah, Sasha A. S. Kjeldsen, Katrine D. Galsgaard, et al.
International Journal of Molecular Sciences (2019) Vol. 20, Iss. 13, pp. 3314-3314
Open Access | Times Cited: 157
Effects of GLP-1 and Its Analogs on Gastric Physiology in Diabetes Mellitus and Obesity
Daniel B. Maselli, Michael Camilleri
Advances in experimental medicine and biology (2020), pp. 171-192
Closed Access | Times Cited: 144
Daniel B. Maselli, Michael Camilleri
Advances in experimental medicine and biology (2020), pp. 171-192
Closed Access | Times Cited: 144
Bertrand Cariou, Christopher D. Byrne, Rohit Loomba, et al.
Diabetes Obesity and Metabolism (2021) Vol. 23, Iss. 5, pp. 1069-1083
Open Access | Times Cited: 143
GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives
Riccardo Nevola, Raffaella Epifani, Simona Imbriani, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 2, pp. 1703-1703
Open Access | Times Cited: 128
Riccardo Nevola, Raffaella Epifani, Simona Imbriani, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 2, pp. 1703-1703
Open Access | Times Cited: 128
Effects on weight loss and glycemic control with SAR441255, a potent unimolecular peptide GLP-1/GIP/GCG receptor triagonist
Martin Bossart, Michael Wagner, Ralf Elvert, et al.
Cell Metabolism (2021) Vol. 34, Iss. 1, pp. 59-74.e10
Open Access | Times Cited: 124
Martin Bossart, Michael Wagner, Ralf Elvert, et al.
Cell Metabolism (2021) Vol. 34, Iss. 1, pp. 59-74.e10
Open Access | Times Cited: 124
Glucagon-like peptide-1 (GLP-1) receptor agonists and neuroinflammation: Implications for neurodegenerative disease treatment
Katherine O. Kopp, Elliot J. Glotfelty, Yazhou Li, et al.
Pharmacological Research (2022) Vol. 186, pp. 106550-106550
Open Access | Times Cited: 114
Katherine O. Kopp, Elliot J. Glotfelty, Yazhou Li, et al.
Pharmacological Research (2022) Vol. 186, pp. 106550-106550
Open Access | Times Cited: 114
Novel therapies with precision mechanisms for type 2 diabetes mellitus
Leigh Perreault, Jay S. Skyler, Julio Rosenstock
Nature Reviews Endocrinology (2021) Vol. 17, Iss. 6, pp. 364-377
Closed Access | Times Cited: 111
Leigh Perreault, Jay S. Skyler, Julio Rosenstock
Nature Reviews Endocrinology (2021) Vol. 17, Iss. 6, pp. 364-377
Closed Access | Times Cited: 111
Recent Advances in Incretin-Based Pharmacotherapies for the Treatment of Obesity and Diabetes
Qiming Tan, Seun Akindehin, Camila E. Orsso, et al.
Frontiers in Endocrinology (2022) Vol. 13
Open Access | Times Cited: 104
Qiming Tan, Seun Akindehin, Camila E. Orsso, et al.
Frontiers in Endocrinology (2022) Vol. 13
Open Access | Times Cited: 104
